27 March 2025 Hillerød, Denmark – Ellab, the leading provider of validation, monitoring, and calibration services and solutions, announces that it has appointed Gergely Sved as its new Chief Executive Officer (CEO), following the departure of Ludvig Enlund. Mr Sved will formally join the company in June, with Chief Financial Officer Andreas Morthorst acting as […]
Former Head of Global R&D at Bayer AG and an exceptional leader with a wealth of experience across biopharma Pivotal time of transition as the company prepares to start clinical development of its first-in-class lead candidate, AT-7687 in obesity AT-7687 offers a new mechanism of action, to set a new standard in obesity management Copenhagen, […]
Highly experienced corporate development leader with a track record of international pharma and biotech deal-making New CEO to drive growth strategy to maximise the potential of drug discovery pipeline to treat cancer London UK, 16 December 2024 – NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces the appointment of Michael Shih as Chief Executive […]
Cambridge, UK, 12 September 2024 – Alchemab Therapeutics (Alchemab), a pharmaceutical company aiming to identify and develop naturally occurring therapeutic antibodies from resilient individuals, today announces that Jane Osbourn, OBE, FMEDSCI, PhD, Alchemab’s Chief Scientific Officer (CSO), has succeeded Young Kwon, PhD as Chief Executive Officer (CEO) and member of the Board. Read more…
Copenhagen, Denmark & New York, USA — 19 Dec 2023— HERVOLUTION Therapeutics ApS (‘HERVOLUTION’), a pioneering biotechnology company focused on developing novel immunotherapies to treat dark genome targets in cancer, aging, and neurodegeneration, today announces the appointment of J. Robert Coleman, PhD, MBA as its Chief Executive Officer. Robert Coleman PhD, MBA, has over 12 […]
